3 New Strong Buy Ratings from Top-Rated Analysts: 06/06/2025

Lucky you! Here’s a complimentary look at what’s trending on our most popular stock screener: 

• 115 compelling reasons why BGC Group (BGC) is our Stock of the Week
• Why analysts are doubling down on Boston Scientific (BSX)
• Unpacking recent price target increases for Myr Group (MYRG)

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

1. Boston Scientific (NYSE: BSX)

Boston Scientific produces a very wide variety of medical devices, from run-of-the-mill pacemakers to advanced stents and brain stimulation systems. BSX is one of the most widely-covered and respected biotech names on Wall Street — and for good reason. One of the Street’s top-rated analysts recently revisited their coverage of the sector — leading to a more optimistic coverage of BSX.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $105.26 — get current quote > 

Max 1-year forecast: $130.00 

Why we’re watching:

• BSX is a rare case in that it enjoys analyst coverage that is both widespread and unanimously positive — it is currently tracked by 16 analysts and has 12 Strong Buy ratings and 4 Buy ratings. See the ratings
• Moreover, the average price target for Boston Scientific shares, at $117.81, implies an 11.93% upside.  
• Citigroup researcher Joanne Wuensch (a top 5% rated analyst) recently doubled down on a prior Strong Buy rating, and increased her price target from $119 to $125.
• Wuensch's model and price target update on Boston Scientific was delivered in a post-quarterly review of names in their Healthcare (Medical Technology) sector coverage area.
• The analyst told readers that things are looking good for the sector as a whole, with fundamentals including volumes, pricing, and Capex holding.
• A few days prior to Wuensch’s revised coverage, Morgan Stanley’s Patrick Wood (a top 15% rated analyst) also reiterated a Strong Buy rating with a $125 price target.
• BSX has a Zen Rating of B, and currently ranks in the top 7% of the more than 4,600 stocks that our rating system tracks.  
• Boston Scientific shows remarkable performance in three categories — it ranks in the top 7% of stocks in terms of Sentiment, the top 11% when it comes to its Artificial Intelligence Component Grade rating, and the top 13% by Growth. (See all 7 Zen Component Grades here >)

2. Myr Group (NASDAQ: MYRG)

Myr Group is a specialty contractors that build and maintains electrical infrastructure across the U.S. and Canada. Its main focuses are high-voltage power lines, substations, and electrical work for large-scale industrial projects. With electrification showing no signs of stopping — coupled with constant calls for grid modernization, MYRG is set to benefit from steady demand.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $156.85 — get current quote > 

Max 1-year forecast: $170.00 

Why we’re watching:

• Myr Group stock currently has 3 Strong Buy ratings, 1 Buy rating, and 1 Hold rating. See the ratings
• KeyBanc equity researcher Sangita Jain (a top 13% rated analyst) reiterated a Strong Buy rating, and increased her price target on the stock from $136 to $163.
• "A strong and clean quarter highlighted by revenue growth and better-than-expected margins" was how Jain summed up the print.
• The analyst told readers that KeyBanc was encouraged by the company's return to growth mode after last year's project challenges.
• Looking ahead, Jain predicted that MYR Group will generate mid-to-high single-digit core revenue growth in both its segments in FY 2025.
• MYRG is also the 4th highest rated stock in the Engineering & Construction industry, which has an Industry Rating of A.  
• Myr Group stock has a Zen Rating of A, and ranks in the 95th percentile of equities on the whole.
• A key driver behind such a high composite score is the stock’s Growth Component Grade rating — in this regard, MYRG ranks in the top 2% of stocks. (See all 7 Zen Component Grades here >)

3. BGC Group (NASDAQ: BGC)

Here’s our Stock of the Week, courtesy of our Zen Investor Editor-in-Chief. BGC Group clears trades across the bond, forex, and equities markets. There’s a high chance that both macro factors and the regulatory shifts will benefit the stock going forward — and once you see how high it ranks in terms of several Component Grade ratings, it’ll soon become apparent why Steve added BGC to his Zen Investor portfolio.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $9.32 — get current quote > 

Max 1-year forecast: $15.00 

Why we’re watching:

• BGC is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why it earned a spot in his exclusive Zen Investor portfolio in a Monday article.
• While Fed rate cuts have been delayed, most experts predict that 4 cuts will occur next year. Moreover, the Trump administration is committed to cutting the red tape that constrains the financial industry — and both of these factors are tailwinds for BGC Group.
• The stock has gone under Wall Street’s radar thus far — only 2 analysts cover it, but both issue Strong Buy ratings, with an average price target of $14.50 — which implies a 56.08% upside. See the ratings
• With the stock’s impressive beat and raise earnings reports, Steve would not be surprised if BGC shares rocketed to levels near the $20 mark.
• At present, the stock has a Zen Rating of A, and ranks in the top 4% of the equities we track.
• For a better idea as to why our system rates it so highly, we have to take a look at its Component Grade ratings. BGC ranks in the top 12% in terms of Growth and Financials.
• However, the stock also ranks quite highly in terms of Artificial Intelligence and Value — in the top 14% and 16%, respectively. (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.